Introduction {#Sec1}
============

Depression is a chronic recurring illness that affects more than 120 million people worldwide. In industrialized societies, approximately five percent of the population experienced a major depressive episode. It is considered that symptoms of depression result from perturbations in monoaminergic neurotransmission. Thus, drugs currently used for treatment of depression include medications that modulate monoaminergic neurotransmission, primarily serotonin and noradrenaline pathways. Unfortunately, their efficacies are unsatisfactory, they produce multiple unwanted side effects and the mechanism of their antidepressant action remains not entirely elucidated (Hollister and Csernansky [@CR12]). Moreover, these drugs require at least 2--4 weeks to produce a clinically meaningful improvement in depressive symptomatology (Rosenzweig-Lipson et al. [@CR58]); therefore, novel therapeutic strategies are sought.

Over the past 20 years, numerous data demonstrated that *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptors may be involved in the mechanism of action of antidepressant treatment (Skolnick et al. [@CR64]; Skolnick [@CR61]; Skolnick et al. [@CR65]). In addition, significantly higher serum and plasma levels of glutamate in patients with depression than those of healthy controls were reported (Kim et al. [@CR19]; Altamura et al. [@CR1]; Mauri et al. [@CR35]; Nowak et al. [@CR39]; Mitani et al. [@CR36]; Siwek et al. [@CR60]). Moreover, increased levels of glutamate in the frontal cortex were demonstrated, implicating abnormality of glutamatergic neurotransmission in the pathophysiological features of major depressive disorder (Sanacora et al. [@CR59]).

Extensive studies have shown that competitive and noncompetitive NMDA receptor antagonists, polyamine site antagonists and inorganic inhibitors of NMDA receptor function, zinc and magnesium, produced antidepressant-like activity in preclinical antidepressant screening procedures (Trullas and Skolnick [@CR69]; Maj et al. [@CR30], [@CR31]; Moryl et al. [@CR37]; Maj et al. [@CR32]; Layer et al. [@CR24]; Kroczka et al. [@CR21], [@CR22]; Nowak et al. [@CR39]; Poleszak et al. [@CR45]; Nowak et al. [@CR40]; Szewczyk et al. [@CR66]; Siwek et al. [@CR60]). Furthermore, an antagonist of the NMDA receptor complex, ketamine, and memantine are effective in human depression (Berman et al. [@CR4]; Zarate et al. [@CR80], [@CR81]). Moreover, CP-101, 606 (a selective antagonist of NR2B subunit of the NMDA receptor) and zinc (non specific antagonist of NMDA receptor) enhance efficacy of antidepressant therapy in major depression (especially treatment resistant subtype) (Nowak et al. [@CR39]; Preskorn et al. [@CR53]; Siwek et al. [@CR60]). However, it should be mentioned that there is a discrepancy between long-term effects of ketamine in clinical observations and experimental paradigms used to evaluate antidepressant activity (e.g., Maeng et al. [@CR29]; Popik et al. [@CR51]; Bechtholt-Gompf et al. [@CR3]).

Unfortunately, both competitive and noncompetitive NMDA antagonists induce severe side effects (Willetts et al. [@CR74]) that limit their applicability as antidepressants for clinical use in humans. Thus, an alternative strategy to the use of competitive and noncompetitive NMDA antagonist was modulation of the glycine co-agonist site at the NMDA receptor (Kemp and Leeson [@CR16]).

Numerous behavioral studies have shown that antagonists and partial agonists at the glycine site exhibit antidepressant-like activity in experimental screening procedures (Trullas and Skolnick [@CR69]; Przegaliński et al. [@CR55]; Vamvakides [@CR70]). Consequently, in this study, we assessed the effects of two glycine B receptor ligands, namely L-701,324 (antagonist) and [d]{.smallcaps}-cycloserine (a partial agonist) on the action of antidepressant drugs with different pharmacological profiles in the forced swim test in mice.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

The experiments were carried out on adult male Albino Swiss mice (25--30 g) purchased from the licensed breeder (Kołacz, Warsaw, Poland). The animals were kept in cages (up to 10 per cage) on a natural day--night cycle with free access to food and water and they were used after 7 days of acclimatization to laboratory conditions. Each experimental group consisted of 8--12 animals. The experimental protocol was approved by the Local Ethics Committee at the Medical University of Lublin (license number 31/2007), and all the procedures were in strict compliance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).

Drug administration {#Sec4}
-------------------

L-701,324 \[7-chloro-4-hydroxy-3-(3-phenoxy)phenylquinolin-2(1*H*)-one, Sigma\] was suspended in a 1% aqueous solution of Tween 80 and administered intraperitoneally (i.p.) 60 min before the tests. [d]{.smallcaps}-cycloserine (DCS, [d]{.smallcaps}-4-amino-3-isoxazolidone, Sigma) and antidepressant drugs: imipramine (IMI, Sigma), fluoxetine (FX, kindly provided by Polpharma, Starogard Gdański, Poland) and reboxetine (RB, Sigma) were dissolved in 0.9% saline freshly before use and administered 60 min before the tests. Control animals received an i.p. injection of saline (vehicle). [d]{.smallcaps}-serine (Sigma, USA) was administered intracerebroventricularly (i.c.v.) 15 min before the test. The i.c.v. administration was performed according to a modified method described by Lipman and Spencer ([@CR27]). Briefly, a 10-μl glass Hamilton microsyringe (type 701) was used. The needle (26 G) was shortened to a length of 7 mm, sharpened and polished to a fine tip. Rigid PVC tubing was put on the needle to limit its penetration to 3 mm. The injection site was approximately 2 mm posterior to an imaginary line intersecting the posterior extent of the orbits of the eyes and 1 mm lateral to the midline. The control animals received an i.p. and i.c.v. injections of saline (vehicle). The volume of vehicles or drug solutions for i.p. and i.c.v. administrations was 10 ml/kg and 5 μl per mouse, respectively. Drug doses and pretreatment schedules were taken from the literature and were confirmed in our previous experiments (Poleszak et al. [@CR47]; Poleszak [@CR44]; Poleszak et al. [@CR49]; Szewczyk et al. [@CR68]).

Serotonergic depletion {#Sec5}
----------------------

In a separate series of experiments, in order to investigate the possible contribution of serotonergic system to the effect of DCS or L-701,324 in the FST, mice were treated with *p*-chlorophenylalanine (*p*-CPA, Sigma). *p*-CPA is known to be an inhibitor of serotonin biosynthesis and depletes serotonin from the brain and other tissues by the selective inhibition of tryptophane hydroxylase (Koe and Weissman [@CR20]; Poleszak [@CR44]). In the present experiments, the mice were injected i.p. either with saline or with *p*-CPA. *p*-CPA was dissolved in 0.9% saline and administered at a dose of 200 mg/kg once daily for 3 consecutive days. On the fourth day, the mice received DCS, L-701,324 or saline injections 60 min before testing.

Noradrenergic lesion {#Sec6}
--------------------

In a separate series of experiments, in order to investigate the possible contribution of noradrenergic system to the effect DCS or L-701,324 in the FST, mice were pretreated with *N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine hydrochloride (DSP-4, Sigma)---a selective noradrenergic neurotoxin (Matsumoto et al. [@CR34]). In the present experiments, the mice were pretreated i.p. with saline or with DSP-4. DSP-4 was dissolved in 0.9% saline and administered at a dose of 50 mg/kg 4 days prior to the test. On the day of testing, the mice received DCS, L-701,324 or saline injections 60 min before testing.

Forced swim test (FST) {#Sec7}
----------------------

The studies were carried out on mice according to the method of Porsolt et al. ([@CR52]). Mice were placed individually into glass cylinders (height 25 cm, diameter 10 cm) containing 10 cm of water, maintained at 23--25°C. The animals were left in the cylinder for 6 min. After the first 2 min, the total duration of immobility was measured during a 4-min test with a summing stopwatch. The mouse was judged to be immobile when it remained floating passively in the water, performing slow motion to keep head above the water.

Locomotor activity {#Sec8}
------------------

The actimeter consists of a cylinder (30 cm diameter, 12 cm high, MultiServ, Lublin, Poland) equipped with two perpendicular infrared light beams located 1.5 cm above the floor. Mice were i.p. pretreated with respective drugs combinations and after a given time period they were placed in the actimeter and locomotor activity (number of interruptions of light beams) was recorded for a period of 10 min after placing the mouse into the actimeter.

Statistical analysis {#Sec9}
--------------------

All experimental results are presented as the mean ± SEM. Comparisons between control and experimental groups were performed by analysis of variance (ANOVA) followed by Student-Neuman-Keuls post hoc test, where appropriate*. P* \< 0.05 was considered as a statistically significant difference.

Results {#Sec10}
=======

Forced swim test {#Sec11}
----------------

### Effect of joint administration of L-701,324 and IMI in the FST {#Sec12}

The effects of a combined administration of L-701,324 and IMI on total duration of immobility in mice are shown in Fig. [1](#Fig1){ref-type="fig"}a \[ANOVA: *F*(3,30) = 6.670, *p* = 0.0014\]. L-701,324 at a dose of 1 mg/kg had no effect on the immobility time in mice. IMI given alone at a dose of 15 mg/kg was also ineffective. L-701,324 (1 mg/kg) injected in combination with IMI (15 mg/kg) significantly reduced the immobility time in mice.Fig. 1Effect of joint administration of L-701,324 and **a** imipramine (IMI), **b** fluoxetine (FX) or **c** reboxetine (RB) on the total duration of immobility in the forced swim test in mice. L-701,324 and antidepressant drugs were administered i.p. 60 min before the test. The*values* represent means ± SEM of 8--9 mice. \*\**p* \< 0.01, \*\*\**p* \< 0.001 versus control (vehicle-treated animals) (Student--Newman--Keuls post hoc test)

### Effect of joint administration of L-701,324 and FX in the FST {#Sec13}

The effects of a combined administration of L-701,324 and FX on total duration of immobility in mice are shown in Fig. [1](#Fig1){ref-type="fig"}b \[ANOVA: *F*(3,31) = 11.59, *p* \< 0.0001\]. L-701,324 at a dose of 1 mg/kg had no effect on the immobility time in mice. FX given alone at a dose of 5 mg/kg was also ineffective. L-701,324 (1 mg/kg) injected in combination with FX (5 mg/kg) significantly reduced the immobility time in mice.

### Effect of joint administration of L-701,324 and RB in the FST {#Sec14}

The effects of combined administration of L-701,324 and RB on total duration of immobility in mice are shown in Fig. [1](#Fig1){ref-type="fig"}c \[ANOVA: *F*(3,29) = 0.2083, *p* = 0.8898\]. L-701,324 at a dose of 1 mg/kg had no effect on the immobility time in mice. RB given alone at a dose of 2.5 mg/kg was also ineffective. L-701,324 (1 mg/kg) injected in combination with RB (2.5 mg/kg) was ineffective in this test.

### Effect of pretreatment with p-CPA on the antidepressant-like activity of L-701,324 in the FST {#Sec15}

The effects of L-701,324 and *p*-CPA on the behavior in the FST are shown in Fig. [2](#Fig2){ref-type="fig"}a \[ANOVA: *F*(3,33) = 7.629, *p* = 0.0005\]. In controls, L-701,324 (4 mg/kg) significantly reduced the immobility time in comparison with saline. The administration of *p*-CPA (200 mg/kg i.p. once a day for 3 consecutive days) did not alter baseline behavior during the FST. However, depletion of serotonin completely blocked the decrease of the immobility time elicited by L-701,324.Fig. 2The effects of pre-treatment of animals with *p*-CPA and DSP-4 on the antidepressant-like effects of **a**--**b** L-701,324 and **c**--**d**[d]{.smallcaps}-cycloserine (DCS) in the forced swim test in mice. *p*-CPA (200 mg/kg, i.p.) was administered once daily for 3 consecutive days. DSP-4 was administered at a dose of 50 mg/kg 4 days prior to the test. The*values* represent means ± SEM of 9--10 mice. \*\**p* \< 0.01, \*\*\**p* \< 0.001 versus control (vehicle-treated animals); ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 versus, respective glycine/NMDA ligand given alone (Student--Newman--Keuls post hoc test)

### Effect of pretreatment with DSP-4 on the antidepressant-like activity of L-701,324 in the FST {#Sec16}

The effects of L-701,324 and DSP-4 on the behavior in the FST are shown in Fig. [2](#Fig2){ref-type="fig"}b \[ANOVA: *F*(3,35) = 7.833, *p* = 0.0004\]. In controls, L-701,324 (4 mg/kg) significantly reduced the immobility time in comparison with saline. The administration of DSP-4 (50 mg/kg i.p.) did not alter baseline behavior during the FST and did not change the reduction of the immobility time elicited by L-701,324.

### Effect of joint administration of DCS and IMI in the FST {#Sec17}

The effects of a combined administration of DCS and IMI on total duration of immobility in mice are shown in Fig. [3](#Fig3){ref-type="fig"}a \[ANOVA: *F*(3,35) = 5.016, *p* = 0.0054\]. DCS at a dose of 2.5 mg/kg had no effect on the immobility time in mice. IMI given alone at the dose of 15 mg/kg was also ineffective. DCS (2.5 mg/kg) injected in combination with IMI (15 mg/kg) significantly reduced the immobility time in mice.Fig. 3Effect of joint administration of [d]{.smallcaps}-cycloserine (DCS) and **a** imipramine (IMI), **b** fluoxetine (FX) or **c** reboxetine (RB) on the total duration of immobility in the forced swim test in mice. DCS and antidepressant drugs were administered i.p. 60 min before the test. The*values* represent means ± SEM of 9--11 mice. \*\**p* \< 0.01 versus control (vehicle-treated animals) (Student--Newman--Keuls post hoc test)

### Effect of joint administration of DCS and FX in the FST {#Sec18}

The effects of a combined administration of DCS and FX on total duration of immobility in mice are shown in Fig. [3](#Fig3){ref-type="fig"}b \[ANOVA: *F*(3,35) = 5.016, *p* = 0.0054\]. DCS at a dose of 2.5 mg/kg had no effect on the immobility time in mice. FX given alone at a dose of 5 mg/kg was also ineffective. DCS (2.5 mg/kg) injected in combination with FX (5 mg/kg) significantly reduced the immobility time in mice.

### Effect of joint administration of DCS and RB in the FST {#Sec19}

The effects of a combined administration of DCS and RB on total duration of immobility in mice are shown in Fig. [3](#Fig3){ref-type="fig"}c \[ANOVA: *F*(3,34) = 0.7426, *p* = 0.5341\]. DCS at a dose of 2.5 mg/kg had no effect on the immobility time in mice. RB given alone at a dose of 2.5 mg/kg was also ineffective. DCS (2.5 mg/kg) injected in combination with RB (2.5 mg/kg) was ineffective in this test.

### Effect of pretreatment with *p*-CPA on the antidepressant-like activity of DCS in the FST {#Sec20}

The effects of DCS and *p*-CPA on the behavior in the FST are shown in Fig. [2](#Fig2){ref-type="fig"}c \[ANOVA: *F*(3,33) = 10.47, *p* \< 0.0001\]. In control animals, DCS (5 mg/kg) significantly reduced the immobility time in comparison with saline. The administration of *p*-CPA (200 mg/kg i.p. once a day for 3 consecutive days) did not alter baseline behavior during the FST. However, depletion of serotonin completely blocked the decrease of immobility time elicited by DCS.

### Effect of pretreatment with DSP-4 on the antidepressant-like activity of DCS in the FST {#Sec21}

The effects of DCS and DSP-4 on the behavior in the FST are shown in Fig. [2](#Fig2){ref-type="fig"}d \[ANOVA: *F*(3,28) = 6.11, *p* \< 0.0025\]. DCS at a dose of 5 mg/kg significantly reduced the immobility time in comparison with saline. The administration of DSP-4 (50 mg/kg i.p. once a day for 3 consecutive days) did not alter baseline behavior during the FST and did not change the reduction of immobility time elicited by DCS.

### Effect of joint administration of [d]{.smallcaps}-serine and IMI in the FST {#Sec22}

The effects of a combined administration of IMI and [d]{.smallcaps}-serine (the glycine B receptor agonist) on the total duration of immobility in mice are shown in Fig. [4](#Fig4){ref-type="fig"}a \[ANOVA: *F*(3,33) = 12.74, *p* \< 0.0001\]. IMI at a dose of 30 mg/kg significantly reduced the immobility time in mice. [d]{.smallcaps}-serine alone, given i.c.v. at a dose of 100 nmol/mouse, had no effect on the immobility time. However, when combined with IMI, it abolished the IMI-induced antidepressant-like effect.Fig. 4Effect of joint administration of [d]{.smallcaps}-serine (DS) and **a** imipramine (IMI), **b** fluoxetine (FX) or **c** reboxetine (RB) on the total duration of immobility in the forced swim test in mice. DS was administered intracerebroventricularly (i.c.v.) 15 min before the test and antidepressant drugs were administered i.p. 45 min before DS. The*values* represent means ± SEM of 9--12 mice. \**p* \< 0.05, \*\*\**p* \< 0.001 versus control (vehicle-treated animals); ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01 versus respective antidepressant drug given alone (Student--Newman--Keuls post hoc test)

### Effect of joint administration of [d]{.smallcaps}-serine and FX in the FST {#Sec23}

The effects of a combined administration of FX and [d]{.smallcaps}-serine on total duration of immobility in mice are shown in Fig. [4](#Fig4){ref-type="fig"}b \[ANOVA: *F*(3,35) = 20.74, *p* \< 0.0001\]. FX at a dose of 10 mg/kg significantly reduced the immobility time in mice. [d]{.smallcaps}-serine given alone at a dose of 100 nmol/mouse i.c.v. had no effect on the immobility time; however, when combined with FX, it abolished the FX-induced antidepressant-like effect.

### Effect of joint administration of [d]{.smallcaps}-serine and RB in the FST {#Sec24}

The effects of a combined administration of RB and [d]{.smallcaps}-serine on total duration of immobility in mice are shown in Fig. [4](#Fig4){ref-type="fig"}c \[ANOVA: *F*(3,36) = 3.777, *p* = 0.0187\]. RB at a dose of 5 mg/kg significantly reduced the immobility time in mice. [d]{.smallcaps}-serine given alone at a dose of 100 nmol/mouse i.c.v. had no effect on the immobility time; however, when combined with RB, it abolished the RB-induced antidepressant-like effect.

Locomotor activity {#Sec25}
------------------

### Effect of combined treatment with L-701,324 and antidepressant drugs (imipramine---IMI, reboxetine---RB or fluoxetine---FX) on spontaneous locomotor activity in mice {#Sec26}

Results presented in Table [1](#Tab1){ref-type="table"}A of the effects of L-701,324, IMI and RB on a locomotor activity were analyzed by 3-way ANOVA repeated measures (between-subjects factors of antidepressant, L-701,324 and repeated factor of time). The administration of antidepressants did not affect activity: *F*(2,48) = 1.98, NS; however, a co-treatment with L-701,324 reduced activity: *F*(1,48) = 4.51, *p* \< 0.05. There was also a significant effect of time: *F*(1,48) = 32.99, *p* \< 0.0001. Since there were no significant effects of any interaction, the post hoc tests were not performed.Table 1Effect of combined treatment with L-701,324 and antidepressant drugs on spontaneous locomotor activity in miceTreatmentDose (mg/kg)Activity counts5 min10 minA Vehicle--122.0 ± 8.9190.1 ± 16.42 L-701,3241121.0 ± 9.78172.1 ± 19.04 Imipramine15137.8 ± 11.09207.6 ± 24.98 L-701,324 + imipramine1 + 15113.6 ± 21.26142.9 ± 30.75 Reboxetine2.5113.3 ± 15.36162.5 ± 21.71 L-701,324 + reboxetine1 + 2.590.0 ± 12.04127.9 ± 16.97B Vehicle--153.1 ± 11.57227.3 ± 18.58 L-701,3241125.1 ± 11.22171.8 ± 19.22 Fluoxetine5132.5 ± 7.91225.0 ± 13.29 L-701,324 + fluoxetine1 + 5169.3 ± 14.0234.2 ± 21.57L-701,324, imipramine, fluoxetine and reboxetine were administered i.p. 60 min before the tests. Control animals received two i.p. injections of respective vehiclesThe values represent means ± SEM of 8--10 mice

Results presented in Table [1](#Tab1){ref-type="table"}B were analyzed by 2-way repeated measures ANOVA (drug as a between groups factor and time as a repeated measures factor) showed a significant effect of time: *F*(1,35) = 139.1, *p* \< 0.0001. Administration of neither FX nor L-701,324 affected the activity. However, there were significant effects of interactions between FX treatment and L-701,324 treatment: *F*(1,35) = 5.35, *p* \< 0.05 as well as between L-701,324 treatment and time: *F*(1,35) = 5.46, *p* \< 0.05. These were mostly due to a decrease in activity of L-701,324-treated mice versus controls in the 10th min of activity measurements (*p* \< 0.05, Newman-Keuls post hoc test).

### Effect of [d]{.smallcaps}-cycloserine (DCS) and L-701,324 on spontaneous locomotor activity in DSP-4 and p-CPA-lesioned mice {#Sec27}

Results from Table [2](#Tab2){ref-type="table"}A (analyzed by 2-way ANOVA repeated measures) revealed significant effects of DSP-4 treatment: *F*(1,40) = 4.2, *p* \< 0.05 and time: *F*(1,40) = 228.9, *p* \< 0.0001. There was also a significant interaction between DCS treatment and time: *F*(1,40) = 6.33, *p* \< 0.05, mostly due to the fact that in the controls, DCS reduced activity in the 5th min as compared with the vehicle treatment in the 10th minute, while such an effect was not observed in DSP-4-treated mice.Table 2Effect of [d]{.smallcaps}-cycloserine and L-701,324 on spontaneous locomotor activity in DSP-4- and *p*-CPA-lesioned miceTreatmentDose (mg/kg)Activity counts5 min10 minA Vehicle--127.7 ± 12.69190.5 ± 23.92 DSP-45095.25 ± 8.66143.3 ± 11.28 [d]{.smallcaps}-cycloserine5116.3 ± 10.43199.7 ± 19.68 [d]{.smallcaps}-cycloserine + DSP-45 + 50109.5 ± 8.60181.3 ± 9.82B Vehicle--114.4 ± 9.77170.4 ± 16.31 DSP-450123.6 ± 11.16197.1 ± 14.41 L-701,3244136.6 ± 16.09183.5 ± 27.12 L-701,324 + DSP-44 + 50142.4 ± 13.03201.8 ± 23.46C Vehicle--138.4 ± 12.20207.7 ± 21.91 *p*-CPA200120.3 ± 7.63180.7 ± 15.27 [d]{.smallcaps}-cycloserine5118.7 ± 7.89193.5 ± 9.92 [d]{.smallcaps}-cycloserine + *p*-CPA5 + 200119.0 ± 8.22201.7 ± 15.90 L-701,3244129.5 ± 16.99183.7 ± 35.18 L-701,324 + *p*-CPA4 + 200108.4 ± 13.37182.5 ± 30.14*p*-CPA (*p*-chlorophenylalanine, 200 mg/kg, i.p.) was administered once daily for 3 consecutive days. DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine hydrochloride) was administered i.p. at a dose of 50 mg/kg 4 days prior to the test. [d]{.smallcaps}-cycloserine and L-701,324 were administered i.p. 60 min before the testsThe values represent means ± SEM of 10--12 mice

However, the two-way ANOVA repeated measures of the data presented in the Table [2](#Tab2){ref-type="table"}B and C demonstrated only a significant effect of time: *F*(1,38) = 92, *p* \< 0.0001 and *F*(1,54) = 137, *p* \< 0.0001, respectively.

### Effect of combined treatment with [d]{.smallcaps}-cycloserine (DCS) and antidepressant drugs (imipramine---IMI, Fluoxetine---FX, reboxetine---RB) on spontaneous locomotor activity in mice {#Sec28}

Results presented in Table [3](#Tab3){ref-type="table"}A analyzed by 2-way ANOVA repeated measures showed a significant effect of time: *F*(1,36) = 231, *p* \< 0.0001 and a significant interaction between time, DCS and IMI treatments: *F*(1,36) = 8.23, *p* \< 0.01. It appeared that at the 5th min, DCS reduced the activity independently on IMI-co-administration, but at the 10th min of the test, DCS increased it in the controls but decreased it in IMI-co-treated animals. However, the post hoc test did not reveal any changes in activity as compared with vehicle-vehicle controls.Table 3Effect of combined treatment with [d]{.smallcaps}-cycloserine and antidepressant drugs on spontaneous locomotor activity in miceTreatmentDose (mg/kg)Activity counts5 min10 minA Vehicle--135.8 ± 9.32193.7 ± 15.86 [ d]{.smallcaps}-cycloserine2.5114.5 ± 14.10216.1 ± 20.66 Imipramine (IMI)15121.0 ± 11.52193.4 ± 11.99 [ d]{.smallcaps}-cycloserine + IMI2.5 + 15110.3 ± 10.44171.2 ± 18.87B Vehicle--116.3 ± 7.29175.4 ± 11.07 [ d]{.smallcaps}-cycloserine2.5101.2 ± 8.07164.2 ± 12.05 Fluoxetine (FX)5111.4 ± 7.15174.3 ± 15.15 [ d]{.smallcaps}-cycloserine + FX2.5 + 5111.0 ± 6.72166.3 ± 11.93C Vehicle--96.4 ± 8.24156.0 ± 13.62 [ d]{.smallcaps}-cycloserine2.5109.7 ± 7.28183.5 ± 10.01 Reboxetine (RB)2.599.5 ± 4.83164.9 ± 11.05 [ d]{.smallcaps}-cycloserine + RB2.5 + 2.5111.5 ± 6.11182.4 ± 14.06L-701,324, imipramine, fluoxetine and reboxetine were administered i.p. 60 min before the tests. Control animals received two i.p. injections of vehicle (saline)The values represent means ± SEM of 9--10 mice

Results presented in Table [3](#Tab3){ref-type="table"}B and C analyzed by analyzed by 2-way ANOVA repeated measures showed that only the time factor was significant: *F*(1,35) = 257, *p* \< 0.001 and *F*(1,36) = 331, *p* \< 0.0001, respectively.

### Effect of combined treatment with [d]{.smallcaps}-serine (DS) and antidepressant drugs (imipramine---IMI, fluoxetine---FX, reboxetine---RB) on spontaneous locomotor activity in mice {#Sec29}

Results presented in Table [4](#Tab4){ref-type="table"}A analyzed by 3-way ANOVA repeated measures showed a significant effect of time: *F*(1,48) = 113.6, *p* \< 0.0001 and of DS treatment: *F*(1,48) = 10.38, *p* \< 0.01. The latter effects could be attributed to a decrease in activity in DS-treated animals independently of the time and the antidepressant treatment.Table 4Effect of combined treatment with [d]{.smallcaps}-serine and antidepressant drugs on spontaneous locomotor activity in miceTreatmentDose nmol/mouse (i.c.v.)/mg/kg (i.p.)Activity counts5 min10 minA Vehicle--116.9 ± 7.95182.9 ± 12.74 [ d]{.smallcaps}-serine (i.c.v.)10075.67 ± 13.29121.2 ± 19.04 Imipramine (i.p.)30110.1 ± 14.94138.0 ± 20.34 [ d]{.smallcaps}-serine + imipramine100 + 3073.0 ± 10.25117.8 ± 11.93 Fluoxetine (i.p.)10121.9 ± 9.15186.3 ± 15.60 [ d]{.smallcaps}-serine + fluoxetine100 + 10113.7 ± 11.32148.0 ± 17.52B Vehicle--91.33 ± 13.56149.7 ± 20.0 [ d]{.smallcaps}-serine (i.c.v.)10096.0 ± 8.26141.1 ± 17.02 Reboxetine (i.p.)5101.7 ± 6.05167.0 ± 7.45 [ d]{.smallcaps}-serine + reboxetine100 + 593.90 ± 10.48119 7 ± 16.00Imipramine, fluoxetine and reboxetine were administered i.p. 60 min and [d]{.smallcaps}-serine was administered i.c.v. 15 min before the tests. Control animals received saline in either two i.p. injections or i.p. and i.c.v. injections given at respective timesThe values represent means ± SEM of 9--10 mice

Results presented in Table [4](#Tab4){ref-type="table"}B analyzed by 2-way ANOVA repeated measures showed significant effects of time: *F*(1,34) = 126, *p* \< 0.0001 and of the interaction between time and DS treatment: *F*(1,34) = 9.28, *p* \< 0.01. The latter effect could be explained by a significant decrease in activity in the 10th min in DS + RB group as compared with RB treated group. However, the post hoc test did not reveal any changes in activity as compared with vehicle-treated controls.

Discussion {#Sec30}
==========

A growing amount of data supports the role of the excitatory glutamatergic neurotransmission in the pathophysiology of depressive disorders. In the clinical studies, disturbances of the glutamate level in depressed patients were found (Mathis et al. [@CR33]; Altamura et al. [@CR1]; Levine et al. [@CR25]). The brain NMDA receptor abnormalities in human suicide victims (Nowak et al. [@CR38]) and major depressives (Law and Deakin [@CR23]; Karolewicz et al. [@CR14]; Feyissa et al. [@CR10]; Karolewicz et al. [@CR15]) were observed. Moreover, a noncompetitive NMDA antagonist, ketamine, produced rapid and sustained antidepressant effects in depressed patients (Berman et al. [@CR4]; Zarate et al. [@CR80]; Phelps et al. [@CR43]; Price et al. [@CR54]), as well as reports that riluzole, which inhibits glutamate release, is effective in patients with bipolar depression (Zarate et al. [@CR78], [@CR79]). Recently, the antidepressant effect of NR2B subunit antagonist, traxoprodil (CP-101, 606) was demonstrated in patients unresponsive to a serotonin selective reuptake inhibitor (Kemp and McKernan [@CR17]; Preskorn et al. [@CR53]).

Numerous reports from preclinical studies have documented the antidepressant-like activity of structurally diverse NMDA receptor antagonists in animal behavioral paradigms. Thus, NMDA channel blockers (dizocilpine), a competitive antagonist of NMDA receptor (AP-7, CGP 37848), a polyamine site antagonist (eliprodil), divalent-cation antagonists (Mg^2+^, Zn^2+^) and a glycine site antagonist (L-701,324), and partial agonist (DCS) were all active in the FST (Skolnick et al. [@CR62]; Trullas and Skolnick [@CR69]; Kroczka et al. [@CR22]; Paul and Skolnick [@CR42]; Poleszak et al. [@CR45], [@CR46]). Additionally, the glycine partial agonist 1-aminocyclopropanecarboxylic acid (ACPC) produced a more rapid onset of action in the chronic mild stress model than it was typically observed for biogenic-amine-based agents (Papp and Moryl [@CR41]).

The glycine binding site is the regulatory domain of the NMDA receptor complex with affinity for the endogenous ligands, glycine (or [d]{.smallcaps}-serine, another endogenous agonist of the glycine site) (Wood et al. [@CR75], [@CR76]). Activation of this site by glycine or [d]{.smallcaps}-serine is absolutely required for NMDA receptor activation by [l]{.smallcaps}-glutamate (Kemp and Leeson [@CR16]). It was proved that glycine receptor antagonists and partial agonists have favorable safety profile compared with competitive and noncompetitive NMDA receptor antagonists (Hawkinson et al. [@CR11]; Danysz and Parsons [@CR8]; Bordi et al. [@CR5]; Beardsley et al. [@CR2]) making them a potential candidates for new antidepressant drugs (Kemp and Leeson [@CR16]; Danysz and Parsons [@CR8]).

In the experimental screening procedures, both full glycine antagonist (L-701,324) and partial agonists at the glycine site (ACPC, DCS) exhibit activity comparable to that of clinically used antidepressants (Trullas and Skolnick [@CR69]; Przegaliński et al. [@CR55]; Vamvakides [@CR70]). In mice the effective dose of L-701,324 in this test was 2 mg/kg (Przegaliński et al. [@CR56]), which was confirmed in our previous study (Poleszak et al. [@CR48]). DCS, a partial agonist of glycine site of the NMDA receptor complex (Hood et al. [@CR13]) was also active in the FST (an effect comparable to that observed with IMI (Vamvakides [@CR70]). Its antidepressant-like activity was first shown in tuberculosis patients (Kendig et al. [@CR18]; Lewis et al. [@CR26]) and provides indirect support for the hypothesis that glycine site partial agonists may be potentially useful as antidepressants (Trullas and Skolnick [@CR69]; Skolnick et al. [@CR63]). As partial agonist DCS may act as agonist or antagonist of the glycine B receptor depending on the dose, that is, a lower dose acts as agonist but higher doses act as antagonist of glycine binding site of the NMDA receptor (Hood et al. [@CR13]; Watson et al. [@CR72]; Emmett et al. [@CR9]). In our previous study, the effective dose of DCS in the FST was the dose 5 mg/kg, while the lower dose (2.5 mg/kg) was not effective itself, but potentiated the antidepressant effects of magnesium or zinc (Poleszak et al. [@CR49]; Szewczyk et al. [@CR68]).

In the present study, we have demonstrated the effects of glycine site ligands (L-701,324 and DCS) on the action of antidepressants with different pharmacological profiles: IMI---a nonselective serotonin/noradrenaline reuptake inhibitor (Westenberg [@CR73]), FX---a selective serotonin reuptake inhibitor (SSRI) (Rickels and Schweizer [@CR57]) and RB---a potent, selective, and specific noradrenergic reuptake inhibitor (NARI) (Versiani et al. [@CR71]). L-701,324 and DCS given with RB (administered in subeffective doses) did not change the behavior of animals in the forced swim test, the behavioral despair procedure commonly used to detect antidepressant agents (Borsini and Meli [@CR6]). However, a potentiating effect was seen when both tested glycine site ligands were given jointly with IMI or FX in this test. This apparent potentiation was manifested as a reduction of the immobility time, but no increase in locomotor activity was evidenced. Similarly, such interaction was demonstrated between ionic NMDA antagonists zinc and magnesium with antidepressants in the FST (Poleszak [@CR44]; Szewczyk et al. [@CR67]).

In the present study, in order to confirm a possible contribution of the serotonergic system to the antidepressive effect of DCS and L-701,324, mice were pretreated with *p*-CPA, an inhibitor of serotonin synthesis or with DSP-4, a selective noradrenergic neurotoxin, and examined in the FST. The lesion of noradrenaline nerve terminals produced by DSP-4 did no alter the baseline activity or influence antidepressant-like action caused by L-701,324 or DCS. The depletion of serotonin by *p*-CPA did not alter baseline activity in the FST; however, completely antagonized the antidepressant-like action caused by L-701,324 and DCS. Thus, we proved that interaction with serotonergic, but not noradrenergic system is necessary for antidepressant-like activity of glycine/NMDA site ligands.

Our recent study has demonstrated that the activation of the NMDA receptor complex by [d]{.smallcaps}-serine blocks the antidepressant-like effect of an antagonist of the glycine/NMDA receptor L-701,324 and ionic antagonists, such as zinc and magnesium, in the FST (Poleszak et al. [@CR48], [@CR49], [@CR50]). Now we show that the antidepressant-like effects of IMI, FX and RB were abolished by [d]{.smallcaps}-serine pretreatment. Thus, these data indicate that antidepressant activity of both serotonin and noradrenaline-based antidepressant are related to the mechanism connected with a reduction of the activity of the NMDA receptor complex (particularly glycine/NMDA sites). Contrary to this notion, Boulay et al. ([@CR7]) demonstrated the antidepressant-like action of glycine transporter type 1 inhibitor SSR103800 which may indicate that activation of glycine/NMDA receptor is related to an antidepressant activity. However, the glycine/NMDA receptor dependence of the antidepressant-like action of SSR103800 in the FST was not demonstrated (e.g., antagonism by glycine/NMDA antagonists). The discrepancy between present data and that of Boulay et al. ([@CR7]) may also be due to the use of different species (mice vs. rats, gerbils). The interaction between NMDA receptor and serotonergic pathway is more obvious than NMDA receptor and noradrenergic one (Yan et al. [@CR77]). There is emerging evidence that the interaction between excitatory amino acids and serotonin may be important for the control of many brain activities. Both NMDA and non-NMDA receptor antagonists have been found to release serotonin and to increase its turnover in some brain structures (Löscher et al. [@CR28]).

To summarize, the present study demonstrates complex interaction between glycine/NMDA receptor ligands and conventional serotonin/noradrenaline-based antidepressants in the FST. While glycine/NMDA receptor functional antagonists enhance an antidepressant-like action of serotonin, but not noradrenaline-based antidepressants and their such activity depends on serotonin but not noradrenaline pathway, the antidepressant-like activity of both types of antidepressants rely on the dampening of the NMDA receptor complex. This study may provide some guidelines about how to optimally use combinations of the NMDA receptor antagonists and biogenic amine-based antidepressant drugs. The NMDA receptor antagonists as antidepressants may be on the near horizon, and the ability to use lower doses of, e.g., traxoprodil when combined with the appropriate agent may be an interesting approach to antidepressant therapy.
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